Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on May 6, 2025
Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes
GlobeNewswire
·
May 6, 2025
Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK …
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
GlobeNewswire
·
May 6, 2025
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a …
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE
GlobeNewswire
·
May 6, 2025
KUALA LUMPUR, MALAYSIA, May 06, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that it entered into an Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS …
Mind Lab PRO Under Review: Is Mind Lab Pro® v4.0 Universal Nootropic Brain Booster Safe? Best Nootropics Supplement
GlobeNewswire
·
May 6, 2025
Royal Leamington Spa, May 06, 2025 (GLOBE NEWSWIRE) -- Mind Lab Pro is a nootropic pill containing relatively high concentrations of eleven distinct nootropic substances. It promises to help the following: Focus Energy Mood’s Calmness Memory Clarity …
Italfarmaco Announces U.S. FDA Grants Fast Track Designation to Givinostat in Treatment of Polycythemia Vera
GlobeNewswire
·
May 6, 2025
MILAN, Italy, May 6, 2025 – Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to givinostat for the treatment of patients with polycythemia vera (PV), a rare haematologic cancer, for …
ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
GlobeNewswire
·
May 6, 2025
MELBOURNE, Australia, May 06, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of viral respiratory infections, announces today that it has appointed Kenny …
Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier
GlobeNewswire
·
May 6, 2025
CAMBRIDGE, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma Company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of …
Essential Pharma strengthens management team with appointment of Duncan Ferguson as Vice President, Commercial
GlobeNewswire
·
May 6, 2025
Egham, UK – 6th May 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Duncan Ferguson as Vice President, …
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
GlobeNewswire
·
May 6, 2025
Dr. Hasskarl to lead global Phase 3 MO-TRANS study evaluating mocravimod as an adjunctive treatment to allo-HCT in AML Saint-Louis, France and Dublin, Ireland – 6th May 2025– Priothera Ltd., a late-stage biopharma company pioneering the development of …
New Analysis Published in Nature Medicine Demonstrates Advantages of Nationwide Coronary CTA Strategy with Heartflow FFRCT in Over 90,000 Patients with Coronary Artery Disease
GlobeNewswire
·
May 6, 2025
MOUNTAIN VIEW, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced two-year data from FISH…
Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy
GlobeNewswire
·
May 6, 2025
Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio Rome, Italy - 6 May 2025 – Angelini Ventures, the corporate venture firm of Angelini …
TestoPrime Review and Results: A 30 Day Test By WhatBest Reveals Results Of Using TestoPrime For 1 Month.
GlobeNewswire
·
May 6, 2025
New York, May 06, 2025 (GLOBE NEWSWIRE) -- WhatBest, a leading product review and comparison platform, has published a detailed 30-day user review of TestoPrime, a natural testosterone support supplement gaining traction among men looking to boost energy, …
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
GlobeNewswire
·
May 6, 2025
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy …
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy
GlobeNewswire
·
May 6, 2025
Last patient first visit (LPFV) marks completion of enrollment of 127 adult and elderly patients in the randomized, placebo-controlled trial -- topline data is expected in Q4 2025 This study builds on Phase 2a proof-of-concept results, which showed a …
Philips delivers on Q1 results, with ongoing order intake growth
GlobeNewswire
·
May 6, 2025
May 6, 2025 Q1 2025 Group performance Group sales EUR 4.1 billion, reflecting a 2% decline in comparable sales growth mainly due to China; slightly ahead of company outlook due to Personal Health growth and royalty phasing Comparable order intake increased …
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
GlobeNewswire
·
May 6, 2025
A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 …